This site is for customers in Japan. Customers in other regions, please go to Global page.
HOME > Product search results > Code No. CY-8078 CircuLex Mouse/Rat PCSK9 ELISA Kit

Code No. CY-8078

CircuLex Mouse/Rat PCSK9 ELISA Kit

Price

¥98,000

Availability (in Japan)

1-9

(In Japan at 00:05,
Nov 29, 2020 in JST)

Size

96 assays

Data

  • Concentrations of mouse PCSK9 in Balb/c mice serum. (n = 20)

Components Microplate, Wash Buffer, Dilution Buffer, Mouse PCSK9 Standard, HRP conjugated Detection Antibody, Substrate Reagent, Stop Solution
Intended use This Kit is used for the quantitative measurement of Mouse and Rat PCSK9 in serum, plasma, cell culture medium and other biological media.
Storage temp. 4°C Manufacturer MBL
Animal species
[Gene ID]
Mouse,Rat
Sample Serum, Plasma, Cell culture medium, Other biological media
Measurement range 0.094~6 ng/mL
Sensitivity 38.1 pg/mL~
Related products CY-8079 CircuLex Human PCSK9 ELISA Kit
CY-8150 CircuLex PCSK9-LDLR in vitro Binding Assay Kit
CY-M1032 Anti-PCSK9 prodomain (Human) mAb
CY-M1033 Anti-PCSK9 (Human) mAb
CY-R2311 PCSK9 D374Y in culture medium
CY-R2330 PCSK9 Wild Type (Human)
CY-R2331 PCSK9 D374Y
CY-R2333 PCSK9 R194A
CY-R2340 LDLR EGF-AB domain
CY-8112 CircuLex Human STAP1 ELISA Kit
CY-8153 CircuLex Human PCSK9 Functional Assay Kit
Citations
  1. Chen XW et al. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. Elife. 2, e00444 (2013)(PMID:23580231)
  1. Carrier B et al. Alpha-lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats. PLoS One. 9, e90863 (2014)(PMID:24595397)
  1. Sasaki M et al. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways. Arterioscler Thromb Vasc Biol. 34, 1171-8 (2014)(PMID:24675665)
  1. Galabova G et al. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS One. 9, e114469 (2014)(PMID:25474576)
  1. Berger JM et al. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis 239, 252-9 (2015)(PMID:25621930)
  1. Butkinaree C et al. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem. 290, 18609-20 (2015)(PMID:26085104)
  1. An D et al. Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Sci Rep. 5, 17559 (2015)(PMID:26691006)
  1. Haas ME et al. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation 134, 61-72 (2016)(PMID:27358438)
  1. Ngo  Sock ET et al. Combined Effects of Rosuvastatin and Exercise on Gene Expression of Key Molecules Involved in Cholesterol Metabolism in Ovariectomized Rats. PLoS One. 11, e0159550 (2016)(PMID:27442011)
  1. Lintner NG et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol. 15, e2001882 (2017)(PMID:28323820)
  1. Xu YX et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis 268, 196-206 (2018)(PMID:29183623)
  1. Yang SH et al. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol. 17, 48 (2018)(PMID:29618348)
  1. Ding Z et al. PCSK9 expression in the ischemic heart and its relationship to infarct size, cardiac function and development of autophagy. Cardiovasc Res. (2018) In press.(PMID:29800228)
  1. Liu Y et al. PCSK9 positively correlates with plasma sdLDL in community-dwelling population but not in diabetic participants after confounder adjustment. Medicine (Baltimore). 98, e15062 (2019)(PMID:30946354)
  1. Momtazi-Borojeni AA et al. Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer. Arch Med Sci. 15, 559-569 (2019) (PMID:31110520)
  1. Momtazi-Borojeni AA et al. Effects of immunization against PCSK9 in an experimental model of breast cancer. Arch Med Sci. 15, 570-579 (2019) (PMID:31110521)
  1. Momtazi-Borojeni AA et al. Therapeutic Effect of Nanoliposomal PCSK9 Vaccine in a Mouse Model of Atherosclerosis. BMC Med. 17, 223 (2019) (PMID:31818299)
  1. Momtazi-Borojeni AA et al. Effects of Immunisation Against PCSK9 in Mice Bearing Melanoma. Arch Med Sci. 16, 189-199 (2019)(PMID:32051723)
  1. Low LD et al. IL-13-driven Alterations in Hepatic Cholesterol Handling Contributes to Hypercholesterolemia in a Rat Model of Minimal Change Disease. Clin Sci (Lond). 134, 225-237 (2020)(PMID:31934720)
  1. Evison BJ et al. A Small Molecule Inhibitor of PCSK9 That Antagonizes LDL Receptor Binding via Interaction With a Cryptic PCSK9 Binding Groove. Bioorg Med Chem. 28, 115344 (2020)(PMID:32051094)
  1. St-Amand R et al. Two weeks of western diet disrupts liver molecular markers of cholesterol metabolism in rats. Lipids Health Dis. 19, 192 (2020)(PMID:32825820)
  1. Ding Z et al. NLRP3 inflammasome via IL-1β regulates PCSK9 secretion. Theranostics. 10, 7100-7110 (2020)(PMID:32641981)
Product category
Research area
Metabolism
Drug discovery
この製品に関するお問い合わせをする

  • The availability is based on the information in Japan at 00:05, Nov 29, 2020 in JST.
  • The special price is shown in red color.
  • Please note that products cannot be ordered from this website. To purchase the items listed in this website, please contact us or local distributers.
  • For storage temparature: RT: room temparature
  • Please note that products in this website might be changed or discontinued without notification in advance for quality improvement.